Skip to main content
. 2007 Nov 5;52(1):312–320. doi: 10.1128/AAC.00467-07

FIG. 1.

FIG. 1.

Comparison of CD4+ T-cell reactivity to HBcAg in patients receiving ADV or the placebo. *, there was a significant increase in the frequencies of IFN-γ-producing CD4+ T cells at TW16 compared to baseline values for ADV-treated patients (P = 0.03). **, at TW40 and TW48, patients receiving ADV had significantly higher frequencies of IFN-γ-producing CD4+ T cells than did patients receiving placebos (P = 0.03). The bars represent means ± SEMs.